Rabies DNA vaccine: No impact of MHC Class I and Class II targeting sequences on immune response and protection against lethal challenge

Vaccine

Volumn 27, Issue 15, 2009, Pages 2128-2137

  Kaur, Manpreet ^a   Rai, Anant ^b   Bhatnagar, Rakesh ^a  

^a JAWAHARLAL NEHRU UNIVERSITY   (India)

^b INDIAN VETERINARY RESEARCH INSTITUTE   (India)

Author keywords

Rabies virus neutralizing antibody (RVNA); Survival; Targeting sequence

Indexed keywords

DNA VACCINE; GAMMA INTERFERON; GLYCOPROTEIN PLUS LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; GLYCOPROTEIN PLUS LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1 PLUS TISSUE PLASMINOGEN ACTIVATOR; GLYCOPROTEIN PLUS TISSUE PLASMINOGEN ACTIVATOR; GLYCOPROTEIN PLUS UBIQUITIN; HYBRID PROTEIN; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 4; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; NEUTRALIZING ANTIBODY; PLASMID DNA; RABIES VACCINE; SIGNAL PEPTIDE; TISSUE PLASMINOGEN ACTIVATOR; UBIQUITIN; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN FUNCTION; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL STRAIN BHK; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DNA IMMUNIZATION; DNA MODIFICATION; DRUG EFFICACY; DRUG POTENCY; DRUG TARGETING; FEMALE; GENE FUSION; GENETIC TRANSFECTION; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; IN VIVO STUDY; INTRACELLULAR TRANSPORT; MOLECULAR CLONING; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN TARGETING; PROVOCATION TEST; RABIES; RABIES VIRUS; T LYMPHOCYTE ACTIVATION; TH1 CELL; TH2 CELL;

ANIMALS; ANTIBODIES, VIRAL; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE; CRICETINAE; FEMALE; GENES, MHC CLASS I; GENES, MHC CLASS II; IMMUNOGLOBULIN ISOTYPES; LYSOSOME-ASSOCIATED MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; RABIES; RABIES VACCINES; TISSUE PLASMINOGEN ACTIVATOR; UBIQUITIN; VACCINES, DNA;

EID: 61549115321     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.01.128     Document Type: Article

References (58)

1. Rupprecht C., Hanlon C.A., and Hemachuda T. Rabies re-examined. Lancet Infect Dis 2 6 (2002) 327-343
2. World survey of rabies: No. 32 for the year 1996. Geneva, World Health Organization; 1998 (WHO/EMC/ZDI/98.4).
3. Smith J.S., and Seidel H.D. Rabies: a new look at an old disease. Prog Med Virol 40 (1993) 82-106
4. Chattergoon M., Bare J., and Weiner D.B. Genetic immunization: a new era in vaccines and immunotherapy. FASEB J 11 10 (1997) 753-763
5. Donnely J., Ulmer J.B., Shiver J.W., and Liu M.A. DNA vaccine. Annu Rev Immunol 15 (1997) 617-648
6. MacGregor R.R., Boyer J.D., Ugen K.E., Lacy K.E., Gluckman S.J., Bagarazzi M.L., et al. First human trial of a DNA based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host responses. J Infect Dis 178 1 (1998) 92-100
7. Calarota S., Bratt G., Nordlund S., Hinkula J., Leandersson A.C., Sandström E., et al. Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients. Lancet 351 9112 (1998) 1320-1325
8. Wang R., Doolan D.L., Le T.P., Hedstrom R.C., Coonan K.M., Charoenvit Y., et al. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science 282 5388 (1998) 476-480
9. Mulligan M.J., Russell N.D., Celum C., Kahn J., Noonan E., Montefiori D.C., et al. Excellent safety and tolerability of the human immunodeficiency virus type 1 pGA2/JS2 plasmid DNA priming vector vaccine in HIV type 1 uninfected adults. AIDS Res Hum Retroviruses 22 7 (2006) 678-683
10. Ceberea I., Dorrella L., McShaneb H., Simmonsa A., McCormackc S., Schmidtd C., et al. Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected volunteers. Vaccine 24 4 (2006) 417-425
11. Margalith M., and Vilalta A. Sustained protective rabies neutralizing antibody titers after administration of cationic lipid-formulated pDNA vaccine. Genet Vaccines Ther 4 2 (2006) 1-6
12. R). Vaccine 18 11 (2000) 1059-1066
13. Lodmell D.L., Ray N.B., and Ewalt L.C. Gene gun particle-mediated vaccination with plasmid DNA confers protective immunity against rabies virus infection. Vaccine 16 2 (1998) 115-118
14. Lodmell D.L., and Ewalt L.C. Rabies vaccination: comparison of neutralizing antibody responses after priming and boosting with different combinations of DNA, inactivated virus, or recombinant vaccinia virus vaccines. Vaccine 18 22 (2000) 2394-2398
15. Lodmell D.L., Parnell M.J., Bailey J.R., Ewalt L.C., and Hanlon C.A. Rabies DNA vaccination of non-human primates: post-exposure studies using gene gun methodology that accelerates induction of neutralizing antibody and enhances neutralizing antibody titers. Vaccine 20 17 (2002) 2221-2228
16. Osorio J.E., Tomlinson C.C., Frank R.S., Haanes E.J., Rushlow K., Haynes J.R., et al. Immunization of dogs and cats with a DNA vaccine against rabies virus. Vaccine 17 9-10 (1999) 1109-1116
17. Perrin P., Jacob Y., Aguilar-Sétien A., Loza-Rubio E., Jallet C., Desmézières E., et al. Immunization of dogs with a DNA vaccine induces protection against rabies virus. Vaccine 18 5-6 (1999) 479-486
18. Lodmell D.L., and Ewalt L.C. Post-exposure DNA vaccination protects mice against rabies virus. Vaccine 19 17-19 (2001) 2468-2473
19. Lodmell D.L., Parnell M.J., Weyhrich J.T., and Ewalt L.C. Canine rabies DNA vaccination: a single-dose intradermal injection into ear pinnae elicits elevated and persistent levels of neutralizing antibody. Vaccine 21 (2003) 3998-4002
20. Bahloul C., Taieb D., Diouani M.F., Ahmed S.B., Chtourou Y., B'chir B.I., et al. Field trials of a very potent rabies DNA vaccine which induced long lasting virus neutralizing antibodies and protection in dogs in experimental conditions. Vaccine 24 8 (2006) 1063-1072
21. Fischer L., Minke J., Dufay N., Baudu P., and Audonnet J.C. Rabies DNA vaccine in the horse: strategies to improve serological responses. Vaccine 21 31 (2003) 4593-4596
22. Bahloul C., Ahmed S.B., B'chir B.I., Kharmachi H., Hayouni el A., and Dellagi K. Post-exposure therapy in mice against experimental rabies: a single injection of DNA vaccine is as effective as five injections of cell culture-derived vaccine. Vaccine 22 2 (2003) 177-184
23. Li Z., Howard A., Kelley C., Delogu G., Collins F., and Morris S. Immunogenicity of DNA vaccines expressing tuberculosis proteins fused to tissue plasminogen activator signal sequences. Infect Immun 67 9 (1999) 4780-4786
24. Arruda L.B., Chikhlikar P.R., August J., and Marquest E.T.A. DNA vaccine encoding human immunodeficiency virus-1 Gag, targeted to the major histocompatibility complex II compartment by lysosomal-associated membrane protein, elicits enhanced long-term memory response. Immunology 112 1 (2004) 126-135
25. Rodriguez F., and Whitton J.L. Enhancing DNA immunization. Virology 268 2 (2000) 233-238
26. Delogu G., Howard A., Collins F.M., and Morris S.L. DNA vaccination against tuberculosis: expression of a ubiquitin-conjugated tuberculosis protein enhances antimycobacterial immunity. Infect Immun 68 6 (2000) 3097-3102
27. Rai N., Kaushik P., and Rai A. Development of rabies DNA vaccine using a recombinant plasmid. Acta Virol 49 (2005) 207-210
28. Koldovský O., and Palmieri M. Cortisone-evoked decrease of acid-galactosidase, glucuronidase, N-acetyl-glucosaminidase and arylsulphatase in the ileum of suckling rats. Biochem J 125 (1971) 697-701
29. Rezwan M., Lanéelle M.A., Sander P., and Daffé M. Breaking down the wall: fractionation of mycobacteria. J Microbiol Methods 68 1 (2007) 32-39
30. Rath A., Choudhury S., Batra D., Kapre S.V., Rupprecht C.E., and Gupta S.K. DNA vaccine for rabies: relevance of the trans-membrane domain of the glycoprotein in generating an antibody response. Virus Res 113 2 (2005) 143-152
31. Smith J.S., Yager P.A., and Baer G.M. A rapid fluorescent focus inhibition test (RFFIT) for determining rabies virus-neutralizing antibody. In: Meslin F.X., Kaplan M.M., and Koprowski H. (Eds). Laboratory techniques in rabies (1996), WHO, Geneva, Switzerland 181-192
32. Cox J.H., Dietzschold B., and Schneider L.G. Rabies virus glycoprotein. II. Biological and serological characterization. Infect Immun 16 3 (1977) 754-759
33. Rupprecht C., Wiktor T.J., Johnston D.H., Hamir A.N., Dietzschold B., Wunner W.H., et al. Oral immunization and protection of raccoons (Procyon lotor) with a vaccinia-rabies glycoprotein recombinant virus vaccine. Proc Natl Acad Sci USA 83 20 (1986) 7947-7950
34. Hua R.L., Liua Y., Zhang S.F., Zhang F., and Fooks A.R. Experimental immunization of cats with a recombinant rabies-canine adenovirus vaccine elicits a long-lasting neutralizing antibody response against rabies. Vaccine 25 29 (2007) 5301-5307
35. Gupta V., Tabiin T.M., Sun K., Chandrasekaran A., Anwar A., Yang K., et al. SARS coronavirus nucleocapsid immunodominant T-cell epitope cluster is common to both exogenous recombinant and endogenous DNA-encoded immunogens. Virology 347 1 (2006) 127-139
36. Costa S.M., Azevedo A.S., Paes M.V., Sarges F.S., Freire M.S., and Alves A.M.B. DNA vaccines against dengue virus based on the ns1 gene: The influence of different signal sequences on the protein expression and its correlation to the immune response elicited in mice. Virology 358 (2007) 413-423
37. Golden J.W., Josleyn M.D., and Hooper J.W. Targeting the vaccinia virus L1 protein to the cell surface enhances production of neutralizing antibodies. Vaccine 26 27-28 (2008) 3507-3515
38. Luo M., Tao P., Li J., Zhou S., Guo D., and Pan Z. Immunization with plasmid DNA encoding influenza A virus nucleoprotein fused to a tissue plasminogen activator signal sequence elicits strong immune responses and protection against H5N1 challenge in mice. J Virol Methods (2008) [Epub ahead of print]
39. Sali M., Clarizio S., Pusceddu C., Zumbo A., Pecorini G., Rocca S., et al. Evaluation of the anti-tuberculosis activity generated by different multigene DNA vaccine constructs. Microbes Infect 10 6 (2008) 605-612
40. Ruff A.L., Guarnieri F.G., Staveley-O'Carroll K., Siliciano R.F., and August J.T. The enhanced immune response to the HIV gp160/LAMP chimeric gene product targeted to the lysosome membrane protein trafficking pathway. J Biol Chem 272 13 (1997) 8671-8678
41. Marques E.T., Chikhlikar P., de Arruda L.B., Leao I.C., Lu Y., Wong J., et al. HIV-1 p55Gag encoded in the lysosome-associated membrane protein-1 as a DNA plasmid vaccine chimera is highly expressed, traffics to the major histocompatibility Class II compartment, and elicits enhanced immune responses. J Biol Chem 278 39 (2003) 37926-37936
42. Weissman A.M. Regulating protein degradation by ubiquitination. Immunol Today 18 4 (1997) 189-198
43. Chen Y., Hu D., Eling D.J., Robbins J., and Kipps T.J. DNA vaccines encoding full-length or truncated Neu induce protective immunity against Neu-expressing mammary tumors. Cancer Res 58 9 (1998) 1965-1971
44. Wang S., Taaffe J., Parker C., Solórzano A., Cao H., García-Sastre A., et al. Hemagglutinin (HA) proteins from H1 and H3 serotypes of influenza A viruses require different antigen designs for the induction of optimal protective antibody responses as studied by codon-optimized HA DNA vaccines. J Virol 80 23 (2006) 11628-11637
45. Morimoto K., Kawai A., and Mifune K. Comparison of rabies virus G proteins produced by cDNA-transfected animal cells that display either inducible or constitutive expression of the gene. J Gen Virol 73 (1992) 335-345
46. Xiang Z.Q., Spitalnik S.L., Cheng J., Erikson J., Wojczyk B., and Ertl H.C. Immune responses to nucleic acid vaccines to rabies virus. Virology 209 2 (1995) 569-579
47. Schumacher C.L., Dietzschold B., Ertl H.C.J., Niu H.S., Rupprecht C.E., and Koprowski H. Use of mouse anti-rabies monoclonal antibodies in post-exposure treatment of rabies antibodies I post exposure treatment of rabies. J Clin Invest 84 3 (1989) 971-975
48. Corr M., von Damm A., Lee D.J., and Tighe H. In vivo priming by DNA injection occurs predominantly by antigen transfer. J Immunol 163 (1999) 4721-4727
49. Jondal M., Schirmbeck R., and Reimann J. MHC-I class restricted CTL responses to exogenous antigens. Immunity 5 (1996) 295-302
50. Fu T.M., Ulmer J.B., Caulfield M.J., Deck R.R., Friedman A., Wang S., et al. Priming of cytotoxic T lymphocytes by DNA vaccines: requirement for professional antigen presenting cells and evidence for antigen transfer from myocytes. Mol Med 3 6 (1997) 362-371
51. Gurunathan S., Klinman D.M., and Seder R.A. DNA vaccines: immunology, application, and optimization. Annu Rev Immunol 18 (2000) 927-974
52. Schirmbeck R., and Reimann J. Alternative processing of endogenous or exogenous antigens extends the immunogenic, H-2 class-I restricted peptide repertoire. Mol Immunol 39 3-4 (2002) 249-259
53. Watts C. Capture and processing of exogenous antigens for presentation on MHC molecules. Annu Rev Immunol 15 (1997) 821-850
54. Fernandes D.M., Vidard L., and Rock K.L. Characterization of MHC class II-presented peptides generated from an antigen targeted to different endocytic compartments. Eur J Immunol 30 8 (2000) 2333-2343
55. Castellino F., Boucher P.E., Eichelberg K., Mayhew M., Rothman J.E., Houghton A.N., et al. Receptor-mediated uptake of antigen/heat shock protein complexes results in major histocompatibility complex class I antigen presentation via two distinct processing pathways. J Exp Med 191 11 (2000) 1957-1964
56. + T cells in vivo. J Immunol 166 (2001) 4355-4362
57. Peng S., Trimble C., Ji H., He L., Tsai Y.C., Macaes B., et al. Characterization of HPV-16 E6 DNA vaccines employing intracellular targeting and intercellular spreading strategies. J Biomed Sci 12 5 (2005) 689-700
58. Dobaño C., Rogers W.O., Gowda K., and Doolan D.L. Targeting antigen to MHC Class I and Class II antigen presentation pathways for malaria DNA vaccines. Immunol Lett 111 2 (2007) 92-102